Solvent-detergent filtered (S/D-F) fresh frozen plasma and cryoprecipitate minipools prepared in a newly designed integral disposable processing bag system.
Solvent-detergent (S/D) viral inactivation was recently adapted to the treatment of single plasma donations and cryoprecipitate minipools. We present here a new process and a new bag system where the S/D reagents are removed by filtration and the final products subjected to bacterial (0.2 microm) filtration. Recovered and apheresis plasma for transfusion (FFP) and cryoprecipitate minipools (400 +/- 20 mL) were subjected to double-stage S/D viral inactivation, followed by one oil extraction and a filtration on a S/D and phthalate [di(2-ethylhexyl) phthalate (DEHP)] adsorption device and a 0.2 microm filter. The initial and the final products were compared for visual appearance, blood cell count and cell markers, proteins functional activity, von Willebrand factor (VWF) multimers and protein profile by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Tri (n-butyl) phosphate (TnBP) was quantified by gas chromatography and Triton X-45 and DEHP by high-performance-liquid chromatography (HPLC). General safety tests were by 6.5 mL/kg intravenous injection in rats. The treated plasmas and cryoprecipitates were very clear and the protein content and functionality, VWF multimers and SDS-PAGE profiles were well preserved. TnBP and Triton X-45 were < 1 and <25 ppm, respectively, and DEHP (about 5 ppm) was less than it was in the starting materials. Blood cell counts and CD45, CD61 and glycophorin A markers were negative. There was no enhanced toxicity in rats. Thus, plasma and cryoprecipitate can be S/D-treated in this new CE-marked disposable integral processing system under conditions preserving protein function and integrity, removing blood cells, S/D agents and DEHP, and ensuring bacterial sterility. This process may offer one additional option to blood establishments for the production of virally inactivated plasma components.
El-Ekiaby
M
M
Shabrawishi Hospital Blood Bank, Giza, Egypt.
Sayed
M A
MA
Caron
C
C
Burnouf
S
S
El-Sharkawy
N
N
Goubran
H
H
Radosevich
M
M
Goudemand
J
J
Blum
D
D
de Melo
L
L
Soulié
V
V
Adam
J
J
Burnouf
T
T
D000818:Animals; D001772:Blood Cell Count; D001781:Blood Component Removal / Q000379:methods*; D001793:Blood Preservation / Q000295:instrumentation*; D001797:Blood Protein Electrophoresis; D001798:Blood Proteins / Q000032:analysis; D002851:Chromatography, High Pressure Liquid; D015925:Cryopreservation / Q000295:instrumentation*; D003902:Detergents / Q000032:analysis; D004051:Diethylhexyl Phthalate / Q000032:analysis; D005169:Factor VIII; D005260:Female; D005340:Fibrinogen; D005374:Filtration; D006801:Humans; D008297:Male; D017830:Octoxynol / Q000032:analysis; D010755:Organophosphates / Q000032:analysis; D010949:Plasma; D051381:Rats; D017207:Rats, Sprague-Dawley; D012997:Solvents / Q000032:analysis; D016060:Sorption Detoxification; D038301:Virus Inactivation
D001798:Blood Proteins; D003902:Detergents; D010755:Organophosphates; D012997:Solvents; C026912:cryoprecipitate coagulum; D005169:Factor VIII; D005340:Fibrinogen; D017830:Octoxynol; C009524:tributyl phosphate; D004051:Diethylhexyl Phthalate